Ariad's mTOR And The FDA Committee Seeking Alpha The first is sirolimus (Rapamune), developed by Wyeth for the prophylaxis of organ rejection for ≥13 years old patients receiving renal transplants. There has been some off-label use of this drug. The second mTOR inhibitor drug, everolimus (Afinitor) ... |
